Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

409
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
409
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

1.3K
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

"More guidelines than rules": reconsidering key gaps in the 2025 American College of Rheumatology treatment recommendations for systemic lupus erythematosus: comment on the article by Sammaritano et al.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

A post hoc analysis of BLISS-LN found Belimumab plus mycophenolate mofetil improves kidney outcomes versus placebo plus mycophenolate mofetil in active lupus nephritis.

Kidney international·2026
Same author

Enpatoran, a Toll-like receptor 7/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trial.

Lancet (London, England)·2026
Same author

Efficacy and safety of enpatoran, a Toll-like receptor 7/8 inhibitor, in patients with skin manifestations of cutaneous lupus erythematosus or systemic lupus erythematosus: findings from Cohort A of a multicentre, international, double-blind, placebo-controlled, dose-finding phase 2 trial.

The Lancet. Rheumatology·2026
Same author

Systemic lupus erythematosus: Phase 3 clinical trials to watch.

Med (New York, N.Y.)·2026
Same author

Insights from the BLISS-LN Phase 3 study of biomarker associations with kidney response to belimumab in lupus nephritis.

Kidney international·2026

Related Experiment Video

Updated: May 3, 2026

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

2.6K

Outcome measures in systemic lupus erythematosus.

Sumatha Channapatna Suresh1, Richard Furie1, Sonali Narain1

  • 1Northwell Health Division of Rheumatology, 865 Northern Boulevard, Great Neck, NY 11021, United States; Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, 500 Hofstra Blvd, Hempstead, NY 11549, United States.

Current Opinion in Immunology
|May 1, 2026
PubMed
Summary

Systemic lupus erythematosus (SLE) outcome measures are evolving. New tools offer continuous scoring and align with treatment targets, improving clinical practice for this complex autoimmune disease.

More Related Videos

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

17.7K
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

1.1K

Related Experiment Videos

Last Updated: May 3, 2026

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

2.6K
The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

17.7K
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

1.1K

Area of Science:

  • Rheumatology
  • Clinical Immunology
  • Health Outcomes Research

Background:

  • Systemic lupus erythematosus (SLE) is a complex autoimmune disease with variable multisystem involvement and risk of organ damage.
  • Standardized SLE disease activity indices are crucial for research but lack widespread clinical integration.
  • Existing measures include traditional indices, dichotomous composite indices, and emerging continuous scoring tools.

Purpose of the Study:

  • To review the evolution of SLE outcome measures.
  • To evaluate the strengths and limitations of current SLE assessment tools.
  • To discuss future directions for comprehensive SLE assessment strategies.

Main Methods:

  • Literature review synthesizing the development of SLE outcome measures.
  • Evaluation of traditional and emerging SLE disease activity indices.
  • Discussion of organ-specific measures, patient-reported outcomes, and damage indices.

Main Results:

  • Traditional indices provide objective disease activity measures.
  • Composite indices differentiate therapeutic response.
  • Emerging tools like SLE Disease Activity Score offer continuous scoring aligned with treat-to-target goals.
  • Patient-reported outcomes and damage indices complement global assessments but are underutilized.

Conclusions:

  • There is a need for unified, actionable SLE assessment metrics.
  • Future directions include integrating biomarkers, imaging, and digital health innovations.
  • Developing comprehensive, clinically feasible, multidimensional assessment strategies is essential for improved SLE management.